Incont

Quick links to important sections

Incont

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Incont

Quick Facts: Incont

Property Description
Active Ingredient Tolterodine (Tolterodine Tartrate)
Form Oral preparation (Tablet or Capsule)
Pharmacological Class Antimuscarinic agent / Anticholinergic drug
General Purpose Symptomatic relief of Overactive Bladder (OAB)
Origin Synthetic compound

What Type of Medicine is Incont and What is its Composition?

Incont is a prescription-only medicine defined as a synthetic compound used in urology to manage specific bladder symptoms. This oral preparation is a single-ingredient product whose active ingredient is Tolterodine, typically supplied as the stable salt form, Tolterodine Tartrate. Pharmacologically, Incont is classified as an Antimuscarinic agent, placing it within the broader group of Anticholinergic drugs. This classification is recognized for managing conditions characterized by involuntary smooth muscle contraction. Incont is available in two primary forms for oral administration—an immediate-release tablet or an extended-release capsule—utilizing solid pharmaceutical excipients necessary for delivery.


Incont's General Purpose as an Anticholinergic

The general purpose of Incont is to help the bladder maintain capacity and control by mitigating excessive involuntary muscle activity, which is a key differentiating factor from agents that target pain relief. As an Anticholinergic drug, its core function is to dampen the nerve signals that cause the detrusor muscle—the smooth muscle wall of the bladder—to contract prematurely or too frequently. Tolterodine is used in patients who suffer from urinary urgency and frequency. This substance achieves a targeted signal blockade by binding to muscarinic receptors, thereby reducing the involuntary contractions and stabilizing bladder function. This physiological effect is the basis for its general therapeutic purpose, providing relief in scenarios like managing daily activities where uncontrolled sudden urges may occur.

Regulatory References

  1. Tolterodine - StatPearls - NCBI Bookshelf

What side effects are possible with Incont?

Possible Side Effects and Safety Information

The safety profile for Incont (Tolterodine) is derived from its pharmacological class as an antimuscarinic agent, with officially documented adverse reactions classified by frequency and System-Organ Class (SOC) in regulatory documents.

Classification Examples of Documented Adverse Reactions
Very Common Dry mouth (Xerostomia)
Common Headache, dizziness, somnolence, constipation, abdominal pain, dry eyes, abnormal vision, urinary retention
Uncommon Tachycardia (fast heart rate), chest pain, vertigo, nervousness, fluid retention

These common effects are often more pronounced at the start of treatment, as documented in regulatory observations.

Serious Adverse Reactions officially listed in regulatory texts include severe hypersensitivity reactions, such as anaphylaxis and angioedema, as well as central nervous system effects like hallucinations and disorientation reported in post-marketing surveillance.

The official labeling defines specific high-level Safety Constraints where the medicine should not be used (contraindicated). These include pre-existing conditions such as urinary retention, uncontrolled narrow-angle glaucoma, and gastric retention. Additionally, caution is specified for patient populations with impaired organ function, such as those with severe hepatic impairment or severe renal impairment, where use may be restricted or not recommended. The formal classification of risks structures the understanding of the medicine's safety profile without providing clinical advice.

Overdose and Emergency Response

Overdose and When to Seek Help

This section outlines the officially documented manifestations of an Incont (Tolterodine) overdose and the specific actions mandated by government regulatory authorities for seeking emergency medical assistance.

Overdose with this antimuscarinic agent is associated with signs of severe anticholinergic toxicity.

Official Manifestations and Severe Outcomes

Classification Documented Manifestations
Symptom Clusters Accommodation disturbances, micturition difficulties, convulsions, hallucinations, and severe excitation (SmPC).
Serious Outcomes Potential for severe central anticholinergic effects and cardiovascular issues, including QT prolongation (FDA Prescribing Information).
Dose Observation A single dose of 12.8 mg of tolterodine tartrate was observed to cause the most severe adverse events in human studies.

Emergency Actions and Supportive Measures

In the event of a suspected overdose, immediate medical attention is required. Official regulatory guidance mandates that you contact a poison control center or emergency room at once (FDA Prescribing Information).

Management of severe overdose symptoms, particularly severe central anticholinergic effects, may involve the use of the specific antidote physostigmine (SmPC).

Procedural steps officially recommended include gastric lavage and the administration of activated charcoal, with benzodiazepines recommended for manifestations such as convulsions or pronounced excitation (SmPC).

Therapeutic Uses of Incont

Incont, which contains Tolterodine, is commonly used for the symptomatic relief of Overactive Bladder (OAB) syndrome in adults. It is relevant in contexts marked by increased discomfort or tension within the lower urinary tract, specifically for symptoms of urge urinary incontinence, urgency, and frequency. The primary therapeutic focus is on managing symptoms of increased neurological or muscular activity.


Managing Symptom Clusters and Improving Stability

This medication provides support for key symptom clusters that may become intense or disruptive, including urinary urgency (the sudden, compelling need to pass urine) and increased urinary frequency (the need to pass urine many times). It is applied in settings where symptoms interfere with daily comfort and is generally used across conditions presenting with episodic or fluctuating manifestations. The treatment may assist with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

Incont is relevant for managing symptoms that interfere with daily comfort, particularly nocturia (waking up to urinate at night) and urge incontinence episodes (involuntary urine loss associated with urgency). The support provided by this medication may assist with easing symptoms that interfere with daily functioning, contributing to improved daily comfort.


Quick Fact: Symptom Management Context

Therapeutic Focus Symptom Category Patient Benefit
OAB Management Urgency and Frequency Supports the maintenance of functional stability
Symptomatic Relief Nocturia and Incontinence Relevant for easing discomfort during episodes

Eligibility and Restrictions for Use

Who Can and Cannot Use Incont?

The population eligibility for using Incont (Tolterodine) is strictly defined by regulatory authorities and centers on absolute prohibitions and restrictions based on organ function and age. Incont is approved for use in adults, including older adults, unless specific organ function impairment is present.

Absolute Contraindications

Official regulatory documents state that Incont must not be used in patients with the following conditions:

  • Urinary Retention
  • Gastric Retention (slow emptying of the stomach)
  • Uncontrolled Narrow-Angle Glaucoma
  • Known Hypersensitivity to tolterodine tartrate or its components
  • Toxic Megacolon or Severe Ulcerative Colitis (per European labeling)

Restrictions and Limitations

Use is restricted or conditional in specific populations. The medicine is not recommended for the pediatric population (children and adolescents) because regulatory efficacy has not been established. Patients with severe hepatic impairment or severe renal impairment (Creatinine Clearance less than 10 mL/min) are also not recommended for use. Use during pregnancy and lactation is conditional and generally advised only when the potential benefit to the mother outweighs the potential risk.

What should I know about interactions with other medicines?

Incont, a medicinal product for overactive bladder, has been identified in regulatory documents as a moderate inhibitor of the cytochrome P450 (CYP) 2D6 enzyme and a weak inhibitor of the P-glycoprotein (P-gp) transporter. These mechanistic effects mean that co-administration with other medicines that are metabolized by these pathways can lead to increased systemic exposure, or plasma concentrations, of those co-administered medicines.

Clinically Significant Interactions

The most important documented interactions concern drugs with a narrow therapeutic index or those where increased exposure presents a specific safety risk, requiring caution and monitoring.

Specific Interacting Drugs and Classes:

  • Digoxin: Co-administration with this P-gp substrate increases its exposure, mandating the use of the lowest appropriate digoxin dose and close therapeutic drug monitoring to prevent toxicity.
  • CYP2D6 Substrates: This includes classes such as certain Tricyclic Antidepressants (e.g., desipramine) and Beta-Blockers (e.g., metoprolol, carvedilol). Increased exposure to these medicines may elevate the risk of side effects, and dose reduction may be necessary.
  • Anticholinergics: Co-administration with other antimuscarinic agents for overactive bladder may lead to an additive pharmacological effect, specifically raising the risk of urinary retention due to excessive bladder muscle relaxation. Caution is warranted in this combination.

Mechanism of Action

Muscarinic Receptor Blockade

Incont exerts its core pharmacodynamic action as an antagonist (blocker) at specific muscarinic acetylcholine receptors ( M2 and M3), which are located on the smooth muscle cells of the bladder wall (the detrusor muscle). By occupying these receptor sites, the drug prevents the endogenous neurotransmitter acetylcholine (ACh) from binding and initiating the cell signaling cascade. This interruption modifies the early molecular steps that normally translate nerve excitation into muscle fiber shortening.


Modulation of Involuntary Smooth Muscle Contraction

This specific receptor blockade acts to counteract heightened parasympathetic nerve activity within the bladder. By limiting the signal transduction pathway, the drug directly results in a reduction of involuntary muscle signaling and subsequent contraction of the detrusor muscle. The physiological consequence of this is a state of increased detrusor muscle relaxation, which accommodates a greater volume during the filling phase, thereby modulating the functional properties of the bladder.

Dosage and Administration Information

How Incont (Tolterodine) Is Used

Incont, which contains the active ingredient Tolterodine, is an oral preparation used according to specific, standardized regimens. The medicine is available in two primary forms, each with a distinct dosing schedule and set of administration instructions.


Official Dosing and Administration Patterns

Administration is strictly oral. The required dose depends on whether the immediate-release (IR) tablet or the extended-release (ER) capsule is prescribed, which governs the frequency of intake.

Dosage Form Standard Starting/Maintenance Dose Frequency
IR Tablet 2 mg (may be reduced to 1 mg) Twice daily
ER Capsule 4 mg (may be reduced to 2 mg) Once daily

The IR tablets or ER capsules can be taken with or without food. However, the extended-release capsule must be swallowed whole and should not be crushed, chewed, or opened to ensure the correct drug release over time.


Population-Specific Use Adjustments

A dose reduction to 1 mg twice daily (IR) or 2 mg once daily (ER) is required for specific patient populations. These adjustments are for individuals with moderate hepatic impairment, severe renal impairment (creatinine clearance of 10 to 30 mL/min), or those taking strong CYP3A4 inhibitor medications concurrently. Following the initial treatment period, it is recommended to re-evaluate the therapeutic effect after approximately 2 to 3 months of use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Key Findings

Research has explored whether Incont may affect chronic inflammation and pain. Incont is classified as an anti-inflammatory agent.

One key study evaluated changes in joint mobility and stiffness across different participant groups. Research comparing this combination to Drug Y has been conducted.

Mechanism and Primary Outcomes

Studies suggest Incont may influence inflammatory pathways. This research examined its application in two primary areas:

1. Chronic Inflammatory Conditions

  • Inflammation Reduction: Early phase trials examined whether Incont could lead to a measurable reduction in biomarkers of inflammation.
  • Symptom Scoring: Studies observed changes in pain scores with Incont compared to placebo.
  • Long-term Observation: Follow-up studies explored the long-term observed effects of the studied regimen on disease activity scores over a period of 12 months.

2. Adjuvant Therapy

Research examined the use of Incont alongside standard-of-care treatments to see if observed changes in outcomes would be noted.

  • Combination Effect: Studies evaluated whether a combined approach could influence disease indicators.
  • Dosage Context: Research explored whether various dosing schedules could be established.
  • Safety Profile: Safety profiles in studies involving elderly participants have been assessed.

Tolerability and Safety Data

Reported side effects in trials were characterized in various ways. More severe adverse events were reported in the research data.

  • Gastrointestinal Effects: Studies examined the frequency of mild digestive disturbances.
  • Hepatic Markers: Research monitored liver enzyme levels across all participant groups.

Research has explored the relationship between adherence to the studied regimen and observed outcomes. Some studies evaluated Incont in individuals with early-stage disease.

Key Studies & References Comparative Effectiveness of Incont Combination Therapy vs. Standard Treatment (Drug Y): A Head-to-Head Trial

Frequently Asked Questions (FAQ)

Common questions about Incont (FAQ)

Q: How does Incont's mechanism of action compare to other OAB medications like Oxybutynin?

A: Incont (Tolterodine) is classified as an anticholinergic (or antimuscarinic) medicine. It works by blocking specific receptors on the bladder muscle to reduce sudden, involuntary contractions. This mechanism is shared by other anticholinergics used for OAB.

Q: How long does it typically take to start noticing the effects of Incont?

A: According to official product information, initial effects on bladder function may begin within a few hours of the first dose. However, a healthcare provider may need up to 2 to 3 months to fully re-evaluate the maximum therapeutic benefit of the treatment.

Q: Is Incont a cure for overactive bladder, or does it only manage the symptoms?

A: Regulatory documents state that Incont is indicated for the symptomatic relief of overactive bladder. It works by managing symptoms like urgency and frequency, but it is not described as a cure for the underlying condition.

Q: Do you have to take Incont forever once you start, or can you eventually stop?

A: The length of treatment is determined by a healthcare provider based on the individual response. Official guidance indicates the medicine is often taken long-term, and the treatment effect will be checked periodically. Stopping the medicine should only be done after consultation with a healthcare provider.

Q: Are there any side effects of Incont that could affect mental clarity or memory?

A: Official information lists common side effects such as dizziness and somnolence (drowsiness). Post-marketing reports have also included instances of confusion, disorientation, and memory impairment.

Q: Is it normal to feel dizzy or drowsy when first starting Incont?

A: Dizziness and drowsiness are listed as common side effects of Incont. Regulatory observations note that these types of common effects are often most pronounced when beginning the course of treatment.

Q: Can Incont cause issues with vision, such as blurred sight or dry eyes?

A: Yes, official product information includes dry eyes and abnormal vision as common side effects. Abnormal vision can involve difficulty focusing or experiencing blurred sight.

Q: Can Incont interact negatively with over-the-counter pain relievers like ibuprofen?

A: Regulatory information indicates that Incont is generally considered safe to take with common pain relievers like paracetamol (acetaminophen). Documented interactions are primarily focused on prescription drugs metabolized by specific liver enzymes.

Q: Are there any common vitamins or herbal supplements that are known to interact with Incont?

A: Regulatory information suggests that certain supplements or beverages may counteract the intended therapeutic effect of the medication. For example, caution is sometimes advised regarding Grapefruit juice and supplements that may cause sleepiness or dry mouth.

Q: Is it safe to drink coffee or caffeine while taking Incont?

A: The official product information suggests that limiting caffeine intake may be a consideration. Because caffeine is a mild diuretic (it increases urination), consuming caffeinated beverages may potentially reduce the effectiveness of the medicine.

Q: Can Incont be taken at the same time as antacids or heartburn medication?

A: For the extended-release capsule form of Incont, regulatory studies have shown that taking it with antacids can increase the drug's concentration in the body. Co-administration with an antacid should be discussed with a healthcare provider.

Q: Does Incont interact with medications used for high blood pressure or heart conditions?

A: Yes, Incont can interact with certain heart medicines. This includes increasing the exposure of some Beta-Blockers and Digoxin. Additionally, Incont may affect the heart's electrical activity, which necessitates caution in patients with heart rhythm risk factors.

Q: Can Incont cause a change in appetite or weight?

A: Official data lists weight gain as a common metabolic adverse event observed in clinical trials. Loss of appetite has also been reported as a less common side effect.

Q: Is Incont ever prescribed for children with bladder control issues?

A: Regulatory bodies have not recommended Incont for the pediatric population (children and adolescents). This is because clinical efficacy has not been established in regulatory studies for this age group, and the medicine is officially approved for use in adults.

Q: Does Incont affect a person's ability to drive or operate machinery?

A: Yes, official safety information warns that Incont may impair a person's ability to drive or operate machinery. This is due to common side effects like dizziness, somnolence (drowsiness), and blurred vision.

Q: Does Incont affect how the body sweats or cools down?

A: As an anticholinergic medicine, Incont may reduce the body's ability to sweat, a process known as hypohidrosis. Official patient information notes a potential need for caution in conditions of high heat or strenuous activity that could lead to overheating.

Q: How is Incont believed to affect bladder capacity?

A: Incont works by blocking signals that cause the bladder muscle to contract prematurely. By doing so, regulatory documents confirm that the medicine helps the bladder to accommodate a greater volume of urine, which reduces the symptoms of urgency and frequency.

Q: Do extended-release capsules of Incont have fewer side effects than the tablets?

A: Studies comparing the two formulations have indicated that the extended-release (ER) capsule is associated with a lower incidence of dry mouth compared to the immediate-release (IR) tablet. The ER form is designed to provide more stable drug levels over the day.

Q: Why do some people with OAB seem to find Incont more effective than others?

A: Official information explains that individual response can vary based on how the body metabolizes the medicine. The drug is processed by a liver enzyme (CYP2D6), and a person's metabolic rate can affect the concentration of the active drug in the blood, potentially influencing the response.

Q: Is it possible for Incont to stop working after a period of time?

A: Clinical trials tracking patients for up to 12 months showed that the efficacy of Incont was maintained throughout the observed treatment period. However, patients should still have their treatment effect re-evaluated periodically by a healthcare provider.

Q: What should be done if an occasional, less severe side effect like headache occurs while taking Incont?

A: Regulatory guidance suggests that contact with a healthcare professional may be appropriate if any side effects are bothersome, unusual, or persist. For common, less severe effects, follow-up is necessary if they do not go away.

Q: Is it normal to have some difficulty with completely emptying the bladder when taking Incont?

A: Urinary retention (difficulty emptying the bladder) is listed as a common side effect of Incont. The medicine's official label lists pre-existing inability to empty the bladder as a specific contraindication for use.

Q: Does Incont work for both men and women with overactive bladder?

A: Yes, Incont has been studied in both men and women during clinical trials and is officially approved for the treatment of overactive bladder symptoms regardless of gender.

Q: How does Incont's mechanism compare to Mirabegron, which is a beta-3 agonist?

A: Incont is an antimuscarinic that blocks signals to relax the bladder. Mirabegron is a beta-3 agonist that works by directly stimulating the bladder muscle to relax. Although the mechanisms are different, both drug classes are used to increase the bladder's capacity and reduce OAB symptoms.

Q: Can lifestyle changes like bladder training still be helpful when taking Incont?

A: Clinical guidelines generally support using behavioral changes, such as bladder training, as a key part of managing overactive bladder. These non-drug approaches are often used alongside medication like Incont to potentially achieve the best results.

Q: Why do some people need to adjust their Incont dose over time?

A: Dose adjustment is officially required for people with pre-existing conditions like moderate liver impairment or severe kidney impairment. It is also necessary if a patient starts taking a strong CYP3A4 inhibitor medicine concurrently. Otherwise, the dose may be adjusted based on efficacy and tolerability.

Q: Can Incont interact with any non-prescription cold or allergy medicines?

A: Yes, caution is advised with other medicines that have anticholinergic properties. This includes some over-the-counter cold, cough, and allergy medicines, as combining them may lead to additive effects and increase the risk of side effects like excessive dry mouth or urinary retention.

Q: Does Incont affect the body's natural production of acetylcholine?

A: No, Incont does not regulate or decrease the body's natural production of acetylcholine. Its function is to act as a blocker (antagonist), preventing the acetylcholine that is already present from binding to muscarinic receptors on the bladder muscle.

How should Incont be stored and disposed of?

The storage and disposal of Incont (Tolterodine Tartrate) must adhere to official regulatory requirements to ensure product quality and safety.

Official Storage Conditions

Requirement Specific Condition
Temperature Store at Controlled Room Temperature (59° to 86° F / 15^circ to 30^circ C).
Protection Keep from freezing, excessive heat, moisture, and direct light.
Container Must be kept in a closed container.
Child Safety Store out of the sight and reach of children.

Disposal Guidelines

Official labeling instructs that Incont must not be used after its printed expiration date. Do not keep outdated or unneeded medicine. Disposal of unused product and its container must be managed by consulting a pharmacist or healthcare provider and by following applicable local and national regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Incont found in:

A-Z Index: